AHCO Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
AdaptHealth Corp (AHCO) is not a strong buy for a beginner, long-term investor at this moment. The company is facing financial challenges, including a significant drop in revenue, net income, and gross margin in the latest quarter. Additionally, there are no strong technical or proprietary trading signals to suggest an immediate buying opportunity. While hedge funds are increasing their positions, the negative catalysts such as legal investigations and lowered analyst price targets outweigh the positives. Holding off on investment until clearer signs of recovery or stability emerge is advisable.
The MACD is below zero and negatively contracting, RSI is neutral at 48.934, and moving averages are converging, indicating no clear trend. The stock is trading near its pivot level of 9.493, with resistance at 10.233 and support at 8.754.
Hedge funds are significantly increasing their positions, with a 1321.21% increase in buying activity over the last quarter.
The company is under investigation for potential breaches of fiduciary duties. Analysts have lowered price targets, citing operational challenges, legal settlements, and a shortfall in adjusted EBITDA. Financial performance in Q4 2025 showed significant declines in revenue, net income, and gross margin.
In Q4 2025, revenue dropped by -1.21% YoY to $846.3M, net income fell by -317.56% YoY to -$100.1M, EPS declined by -317.65% YoY to -0.74, and gross margin decreased by -45.68% YoY to 19.17.
Deutsche Bank lowered the price target to $9.50 from $10.50 with a Hold rating. Canaccord lowered the price target to $14 from $15 but maintained a Buy rating, citing operational improvements but highlighting challenges such as legal settlements and forward investments.
